Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)

• Status: Completed
• Trial end date: 1997-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether hydroxyurea prevents the onset of chronic end organ damage in young children with sickle cell anemia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Hydroxyurea

Criteria

Children with sickle cell disease and between the ages of five and eighteen years.